Back to Directory

TheraCryf

Preclinical orexin-1 addiction therapies and CNS drug discovery

TheraCryf is an AIM-listed biotechnology company developing small-molecule therapies for addiction and other neuropsychiatric conditions.

Its lead orexin-1 receptor antagonist programme is completing preclinical toxicology and regulatory preparations for a first-in-human Phase 1 trial in Australia. An Australian CRO was appointed in October 2026; patient dosing has not yet been confirmed.

Other programmes include dopamine transporter modulators for central fatigue and a legacy grant-supported SFX-01 oncology programme in glioblastoma.

Company Notes

Previously Known As
Evgen Pharma
Member of